Yahoo Finance27d
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
As published in BioXriv, scientists at the Netherlands Cancer Institute have discovered an enzyme that mediates the conversion of LB-100 into the active metabolite endothall. Accordingly ...
Yahoo Finance6d
LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
“Thus far in our Phase 1 clinical trials, LB-100 has shown patient tolerance, with little toxicity, making it a promising candidate as a broad and effective cancer prevention modality.